Nash, Jonathan (2017) Navigating Psychedelic Medicines through (Inter)national Regulation. In: Breaking Convention 2017, 30th June - 2nd July 2017, London.
![[img]](/style/images/fileicons/slideshow.png) |
Slideshow (Powerpoint)
__Client_H$_Documents_Breaking Convention 2017 Final.pptx - Presentation Restricted to Registered users only Download (3MB) | Request a copy |
![[img]](/style/images/fileicons/text.png) |
Text (Slideshow)
__Client_H%24_Documents_Breaking Convention 2017 Final.pdf Restricted to Repository staff only Download (2MB) | Request a copy |
Abstract
Clinical trials using psychedelic substances such as MDMA, marijuana, ketamine and psilocybin to combat mental and physical illnesses can only commence after years of regulatory and ethical hurdle-leaping and face many more before those medicines may be licensed. The impact of the classification of psychedelic substances as having no accepted medical use on the regulatory systems governing clinical research and licensing in the US, Europe and the UK will be considered and possible solutions to the legal impasse will be offered.
| Item Type: | Conference or Workshop Item (Lecture) |
|---|---|
| Uncontrolled Keywords: | Psychedlic medicines, clinical trials, international regulation |
| Subjects: | B200 Pharmacology, Toxicology and Pharmacy M200 Law by Topic |
| Department: | Faculties > Business and Law > Northumbria Law School |
| Related URLs: | |
| Depositing User: | Jonathan Nash |
| Date Deposited: | 04 Sep 2017 09:25 |
| Last Modified: | 01 Aug 2021 07:17 |
| URI: | http://nrl.northumbria.ac.uk/id/eprint/31692 |
Actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
